Promoter holding
64.27%
TP
Trends Pharma Pvt Ltd - Due diligence report
A 360° intelligence report on Buy Sanitab: trust score, financial health, credit view, compliance, directors, growth and distress signals - …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Buy Sanitab — 360° Intelligence Report
Generated from MCA filings & public records83/100
Trust Score
Low Risk
Buy Sanitab is assessed as Low Risk with a Trust Score of 83/100. Buy Sanitab is an active private limited indian non-government company incorporated in 1985, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 10 Jul 2026 from the latest processed filings. Trends Pharma Pvt Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
83/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
54/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 1 open (16.50 Lakh) · 6 satisfied (21.06 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Bank Of Baroda | 2 | 48.0 cr |
| Others | 1 | 48.0 cr |
| Gujarat Industrial Investment Corpn. Ltd. | 1 | 48.0 cr |
| Dena Bank | 2 | 48.0 cr |
| Gujarat Industrial Investment Corpontion Ltd. | 1 | 48.0 cr |
Compliance Score: 54/100 Moderate
- Company status is Active as per MCA.
- Marked ACTIVE non-compliant (INC-22A).
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 2 court forum(s).
- 1 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| DEEPAK LALCHAND BHARWADA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRAGNA DEEPAK BHARWADA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RIDDHI BHARWADA TAINWALA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
1
Capital events
7 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Prawil Laboratories Limited | Associate Company | 74.00% |
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Net margin improved to 61%.
EPFO headcount growing - hiring signal.
Operating for 40+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (54/100).
1 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence74/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment85/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 16.50 Lakh already registered.
- Compliance gaps should be priced into terms.
Investor view92/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
02 Jun 2023
Charge satisfied
Others
15 Dec 2017
Charge created
Others - 7.50 cr
08 Feb 2017
Securities allotted
100000 Equity Shares - 1.00 cr raised
19 Aug 2016
Charge satisfied
Bank Of Baroda
Charge satisfied
Dena Bank
12 May 2016
Securities allotted
23000 Equity Shares - 23.00 Lakh raised
07 May 2016
Charge satisfied
Bank Of Baroda
13 Apr 2016
Securities allotted
75000 Equity Shares - 75.00 Lakh raised
06 Apr 2016
Securities allotted
55000 Equity Shares - 55.00 Lakh raised
31 Mar 2016
Securities allotted
58000 Equity Shares - 58.00 Lakh raised
31 Mar 2010
Director ceased
AMIT BHUPENDRA PARIKH
Director ceased
GAUTAM BHUPENDRA PARIKH
29 Mar 2010
Securities allotted
135000.00 Equity Shares - 1.35 cr raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 7 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Avi Healthcare | U52311MH2009PTC191974 | Mumbai, Maharashtra, India |
| Adit Containers Private Limited | U28100MH1983PTC031185 | Mumbai, Maharashtra, India |
| Narayan Dye Stuff Private Limited | U24119GJ2008PTC053684 | Ahmedabad, Gujarat, India |
| Sanolet Lifecare Private Limited | U24304GJ2020PTC116691 | Ahmedabad, Gujarat, India |
| Sreedevi Wind Farm India Private Limited | U40300TZ2017PTC029225 | Tirupur, Tamil Nadu, India |
| Neobee Solutions Private Limited | U24299KA2021PTC148890 | Bangalore North, Karnataka, India |
| Lhp International Private Limited | U24233WB2010PTC150734 | Kolkata, West Bengal, India |
| Suma Pharmaceuticals Private Limited | U27100MH1991PTC062830 | Ambernath, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Buy Sanitab before audits and certifications: compliance score 54/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Buy Sanitab: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Buy Sanitab - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 83/100, distress signals and MSME payment-delay disclosures - know whether Buy Sanitab pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Buy Sanitab - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Buy Sanitab an active company?
Buy Sanitab has MCA status “Active” with a compliance score of 54/100 (Moderate).
Is Buy Sanitab financially healthy?
Buy Sanitab has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Buy Sanitab?
Its overall Trust Score is 83/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Buy Sanitab?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.
Does Buy Sanitab have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 6 earlier charge(s) stand satisfied.
Is Buy Sanitab up to date with its ROC filings?
Marked ACTIVE non-compliant (INC-22A). Overall compliance score: 54/100 (Moderate).
Is it risky to lend to Buy Sanitab?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
